Coave Therapeutics to Participate in Upcoming Conferences

Coave Therapeutics to Participate in Upcoming Conferences

Paris, France, May 17, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announces that it will participate at the following conferences:

• BIO International Convention, June 5-8

CEO Rodolphe Clerval will be available in Boston for one-to-one meetings with potential partners and investors. Meetings can be scheduled via the partnering system.

• 4^th Annual Gene Therapy for Neurological Disorders Summit Europe, June 6-8

Chief Operating Officer, Patricia Françon, will discuss the challenges of deep brain delivery and distribution of gene therapies and how AAV-ligand conjugates can be used to overcome these challenges and improve efficacy of gene therapies in the CNS.

Presentation Title: Discussing AAV-ligand Conjugates for Improved Efficacy & Distribution in CNS

Date & Time: Thursday June 8 at 9:30 am CEST

Location: Amsterdam, Netherlands

Next Generation Gene Therapy Vectors Summit 2023, June 27-29

CEO Rodolphe Clerval will review post-translational chemical modifications available for capsids, how these improve on-target tropism and discuss how to manage manufacturing issues with chemically modified capsids.

Presentation Title: Guiding the Way: Introducing Post-Translational Modifications to Improve On-Target Tropism

Date & Time: Thursday June 29 at 11:00 am EDT

Location: Boston, MA